Sai Life Sciences Ltd

- There is no direct mention of any current or planned fundraising through debt or equity in the provided transcript. - The company noted a CAPEX spend of Rs. 700 crores for the current year and acknowledged ongoing capital expenditure in the next year, but no specific mention of funding sources was given. - Interest costs have come down recently, suggesting some repayment or refinancing has already taken place, but no new debt issuance was specified. - No comments were made on equity issuance or raising capital through equity markets. - Overall, the discussion touched on investment plans and cash flows but did not reveal any active or upcoming fundraising through debt or equity.

- Sai Life Sciences is undertaking a large CAPEX of ₹700 crores for FY26. - This CAPEX is based on strong visibility from existing products scaling up and late-stage pipeline projects plus clinical inquiries and collaborations. - ₹700 crores CAPEX is for the current year, with CAPEX likely continuing next year though numbers are not finalized. - The CAPEX covers manufacturing expansions including new production blocks (totaling around 450 KL capacity by H2 FY27) and Discovery capacity additions. - Research & Development (R&D) capacity is doubling by next year, and manufacturing capacity is expected to increase by about 80%-90% by FY27. - New capacity additions include 91 KL commissioned recently, 200 KL by Q3 FY27, and 450 KL expected by H2 FY27. - Expansion also includes adding peptides and early-phase formulation capabilities. - The company is diversifying its footprint to reduce concentration risk.

- Sai Life Sciences anticipates sustained growth driven by both existing and late-stage pipeline products with strong visibility from client demand (Page 15). - The company targets a 3-5 year CAGR around 15% across combined CRO and CDMO businesses (Page 11). - Manufacturing capacity is expected to increase by approximately 80-90% by FY'27, supporting volume growth (Page 12, 11). - Process R&D capacity is planned to nearly double by next year, enhancing support for clinical and commercial supply programs (Page 3, 8). - Growth will be fueled by new modalities like oligonucleotides (near commercial), ADCs (late-phase assets), peptides (early clinical stage), and lipids (Page 9). - No major impact is expected from reshoring or US capacity additions on intermediates and APIs supplied by Sai (Page 15). - Business scaling and operating leverage are expected to improve margins toward 28%-30% (Page 4). - Overall, growth is driven by deepening client partnerships, increased scientific depth, and capacity expansions to meet evolving needs (Page 4, 15).

- Sai Life Sciences reported a strong Q1 FY'26 with revenue up 77% YoY, driven mainly by CDMO (113% growth) and CRO (38% growth). - EBITDA surged 305% YoY with margins expanding to 25%, moving towards the targeted 28%-30% margin range as revenues grow. - The company is optimistic about continued growth, backed by strategic investments in capacity expansion (700 crores CAPEX this year) and new modalities like peptides, ADCs, and oligonucleotides. - Management expects steady revenue growth averaging around 15% annually over the next 3-5 years. - Capacity additions (~550 KL expansion by FY'27) support scaling for commercial and clinical supply programs, mitigating capacity constraints. - Profits and operating earnings are expected to improve consistently due to operating leverage, scale efficiencies, and improved productivity. - No specific EPS guidance was provided, but positive profitability trends with PAT turnaround indicate future EPS growth potential.

- The company has better visibility on order book now compared to the past, with increased confidence about utilization levels going forward. - There is no specific mention of a quantified current order book value in the transcript. - The capacity buildup is now more aligned with anticipated orders over the next 12-24 months, indicating strong client commitments. - Late-stage pipeline visibility is strong, supported by existing forecasts, clinical inquiries, and ongoing development programs with large pharma. - The company continues to onboard new large pharma customers and deepen relationships, enhancing order book quality. - The CDMO business remains lumpy and volatile quarter-on-quarter, but growth is driven by both commercialized and existing molecules. - Despite volatility, no one-offs or stock build-ups affecting order flow were reported in Q1 FY'26.